Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus BRISTAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus BRISTAGEN.
AMIKACIN SULFATE vs BRISTAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
2.5 hours (prolonged to 20-40 hours in renal impairment).
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic